Cargando…

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm

Patients with aplastic anemia or hypoplastic myelodysplastic syndrome (MDS) may respond to immunosuppressive therapy, including the anti-CD52 antibody alemtuzumab. We analyzed treatment responses to alemtuzumab in 5 patients with MDS or aplastic anemia (AA) evolving to MDS. Two patients with hypopla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Füreder, Wolfgang, Cerny-Reiterer, Sabine, Sperr, Wolfgang R., Müllauer, Leonhard, Jäger, Eva, Schwarzinger, Ilse, Geissler, Klaus, Valent, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486731/ https://www.ncbi.nlm.nih.gov/pubmed/27743175 http://dx.doi.org/10.1007/s00508-016-1091-9

Ejemplares similares

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H()
por: Valent, Peter, et al.
Publicado: (2013)

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)
por: Herrmann, Harald, et al.
Publicado: (2012)

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
por: Valent, Peter, et al.
Publicado: (2010)

Circulating exosomal microRNAs in acquired aplastic anemia and myelodysplastic syndromes
por: Giudice, Valentina, et al.
Publicado: (2018)

P805: ALEMTUZUMAB IN RELAPSED SEVERE APLASTIC ANEMIA: LONG-TERM RESULTS OF A PHASE II STUDY
por: Aggarwal, N., et al.
Publicado: (2022)

Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The “Seed and Soil” Crosstalk
por: Fattizzo, Bruno, et al.
Publicado: (2020)

Identification of Plasma Thrombopoietin Level and Its Significance in Patients with Aplastic Anemia and Myelodysplastic Syndrome
por: Zhang, Mengying, et al.
Publicado: (2023)

Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea
por: Lee, Jong Wook
Publicado: (2008)

Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia
por: Fattizzo, Bruno, et al.
Publicado: (2021)

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia
por: Wedeh, Ghaith, et al.
Publicado: (2015)

Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report
por: Füreder, Wolfgang, et al.
Publicado: (2020)

Aplastic Anemia in China
por: Liu, Chunyan, et al.
Publicado: (2018)

Quantitative Detection of ID4 Gene Aberrant Methylation in the Differentiation of Myelodysplastic Syndrome from Aplastic Anemia
por: Li, Mian-Yang, et al.
Publicado: (2015)

Hypoplastic myelodysplastic syndrome and acquired aplastic anemia: Immune-mediated bone marrow failure syndromes (Review)
por: Votavova, Hana, et al.
Publicado: (2021)

Quantifying Bone Marrow Fat Fraction and Iron by MRI for Distinguishing Aplastic Anemia from Myelodysplastic Syndromes
por: Zeng, Zhaolong, et al.
Publicado: (2021)

Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis
por: Berger, Daniela, et al.
Publicado: (2021)

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells
por: Stefanzl, Gabriele, et al.
Publicado: (2017)

Quantitative Assessment of Bone Marrow Activity Using (18)F-FLT PET in Aplastic Anemia and Myelodysplastic Syndromes
por: Tasaki, Toshiki, et al.
Publicado: (2022)

Idiopathic Aplastic Anemia: An Update
por: Solomou, Elena E.
Publicado: (2019)

Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia
por: Contejean, Adrien, et al.
Publicado: (2019)

Fatigue, symptom burden, and health‐related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria
por: Escalante, Carmen P., et al.
Publicado: (2019)

Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts
por: Valent, Peter, et al.
Publicado: (2018)

Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study
por: Rogers, Zora R., et al.
Publicado: (2019)

Aplastic anemia: immunosuppressive therapy in 2010
por: Risitano, Antonio M., et al.
Publicado: (2011)

Osteonecrosis of the hip in patients with aplastic anemia.
por: Park, Jeongmi, et al.
Publicado: (2002)

Cephalosporin-induced recurrent aplastic anemia
por: Han, Jimin, et al.
Publicado: (2010)

Ecthyma gangrenosum associated with aplastic anemia.
por: Chun, W. H., et al.
Publicado: (1996)

Aplastic anemia, membranous nephropathy and mercury
por: Rooney, J.
Publicado: (2013)

Child with aplastic anemia: Anesthetic management
por: Kaur, Manpreet, et al.
Publicado: (2012)

Recent advances in treatment of aplastic anemia
por: Shin, Seung Hwan, et al.
Publicado: (2014)

Aplastic anemia in adult and pediatric hematology
por: Niemeyer, Charlotte
Publicado: (2019)

Aplastic Anemia in Triple X Syndrome
por: Aldarwish, Mohammed, et al.
Publicado: (2023)

Molecularly guided treatment of metastatic parotid gland carcinoma in adults
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Measurement for the Area of Red Blood Cells From Microscopic Images Based on Image Processing Technology and Its Applications in Aplastic Anemia, Megaloblastic Anemia, and Myelodysplastic Syndrome
por: Zhao, Yongfeng, et al.
Publicado: (2022)

Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells
por: Grimaldi, Francesco, et al.
Publicado: (2017)

Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56(bright) NK cell subpopulations in patients with acute myeloid leukemia and supports their activation
por: Cuapio, Angélica, et al.
Publicado: (2016)

A Deep Learning Model for the Automatic Recognition of Aplastic Anemia, Myelodysplastic Syndromes, and Acute Myeloid Leukemia Based on Bone Marrow Smear
por: Wang, Meifang, et al.
Publicado: (2022)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1aldp734lvnb664gpv5ial8p2b